Citi lowered the firm’s price target on Sealed Air to $37 from $41 and keeps a Buy rating on the shares. The analyst cut multiples and target prices for North America packagers with heavy food and beverage exposure on the potential impact from Ozempic and other GLP-1 drugs. The firm says the drugs pose a risk to food and beverage volumes. Given the potential market size with 42% of Americans classified as obese, further adoption of the GLP-1 drugs could be an “existential problem” for food-exposed packagers, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SEE:
- Sealed Air price target lowered to $38 from $43 at Truist
- Early notable gainers among liquid option names on September 25th
- Citi Sealed Air to Buy, sees end of negative earnings revisions
- Sealed Air upgraded to Buy from Neutral at Citi
- General Motors upgraded, Oracle downgraded: Wall Street’s top analyst calls
